Alnylam Pharmaceuticals
ALNY
143.82
-4.00
-2.71%
Alnylam Pharmaceuticals
US · ALNY
#627 by market cap
Listed 1970
143.82
-4.00
-2.71%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Quant vs Street three independent views, side by side
StockVane factor grade
B+
Momentum strategy signal
Strong Sell
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
✦ Quant Analyst Revision Trend how this is computed
Deteriorating
3
■ Upgrades■ Downgrades
- 0 upgrades vs 3 downgrades among tracked analyst rating changes.
- Most recent: Truist Financial moved from Buy to Hold on 2026-11-02.
Analyst consensus 25 analysts
Buy
Avg price target 317.34 +120.7%
Price target rangecurrent 143.82
Low199.00
Avg317.34
High455.00
Buy 76%
Hold 24%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-06 | Cantor Fitzgerald | -- | Hold | 290.00 |
| 2026-11-06 | H.C. Wainwright | -- | Buy | 455.00 |
| 2026-11-05 | Piper Sandler | -- | Buy | 410.00 |
| 2026-11-05 | BofA Securities | -- | Buy | -- |
| 2026-11-05 | BMO Capital | -- | Buy | 292.00 |
| 2026-11-05 | H.C. Wainwright | -- | Buy | 455.00 |
| 2026-11-05 | Oppenheimer | -- | Buy | 320.00 |
| 2026-11-04 | Wells Fargo | -- | Hold | 220.00 |
| 2026-11-02 | CCORF | -- | Buy | 323.00 |
| 2026-11-02 | Truist Financial | -- | Hold | 225.00 |
| 2026-11-02 | Barclays | -- | Buy | 380.00 |
| 2026-10-30 | Chardan Capital | -- | Buy | 375.00 |
| 2026-10-30 | Bernstein | -- | Hold | 199.00 |
| 2026-10-30 | UBS | -- | Buy | 329.00 |
| 2026-10-30 | Piper Sandler | -- | Buy | 410.00 |
| 2026-10-30 | Raymond James | -- | Buy | 315.00 |
| 2026-10-30 | Freedom Capital Markets | -- | Buy | 350.00 |
| 2026-10-30 | Morgan Stanley | -- | Hold | 240.00 |
| 2026-10-30 | Goldman Sachs | -- | Buy | 320.00 |
| 2026-10-30 | H.C. Wainwright | -- | Buy | 455.00 |
| 2026-10-30 | Barclays | -- | Buy | 450.00 |
| 2026-10-29 | TD Cowen | -- | Buy | 354.00 |
| 2026-10-29 | BofA Securities | -- | Buy | 287.00 |
| 2026-10-29 | Jefferies | -- | Hold | 250.00 |
| 2026-10-29 | H.C. Wainwright | -- | Buy | 455.00 |
Price target trend monthly average, last 3 years
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-11-02 | Truist Financial | Buy → Hold | 225.00 |
| 2026-10-30 | Bernstein | Buy → Hold | 199.00 |
| 2026-03-15 | Jefferies | Buy → Hold | 330.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-10-29 | -- | ±11.20% | -25.13% (beat) |
| 2026/Q2 | 2026-07-30 | -- | ±10.10% | -28.31% (beat) |
| 2026/Q1 | 2026-04-30 | -- | ±7.83% | +2.76% (in line) |
| 2025/Q4 | 2026-02-12 | -- | ±6.44% | -4.28% (in line) |
| 2025/Q3 | 2025-10-30 | -- | ±10.17% | -6.65% (in line) |
| 2025/Q2 | 2025-07-31 | -- | ±8.25% | +15.43% (beat) |
| 2025/Q1 | 2025-05-01 | -- | ±9.13% | -3.08% (in line) |
| 2024/Q4 | 2025-02-13 | -- | ±7.08% | -0.40% (in line) |
| 2024/Q3 | 2024-10-31 | -- | ±8.42% | -5.29% (in line) |
| 2024/Q2 | 2024-08-01 | -- | ±7.79% | +13.12% (beat) |
| 2024/Q1 | 2024-05-02 | -- | ±8.84% | +0.23% (in line) |
| 2023/Q4 | 2024-02-15 | -- | ±5.44% | -10.19% (beat) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Alnylam Pharmaceuticals discussion 0 comments